Cargando…

Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides

Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disease caused by frameshift or nonsense mutations in the DMD gene, resulting in the loss of dystrophin from muscle membranes. Exon skipping using splice-switching oligonucleotides (SSOs) restores the reading frame of DMD pre-mRNA by gener...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tone, Yuichiro, Mamchaoui, Kamel, Tsoumpra, Maria K., Hashimoto, Yasumasa, Terada, Reiko, Maruyama, Rika, Gait, Michael J., Arzumanov, Andrey A., McClorey, Graham, Imamura, Michihiro, Takeda, Shin'ichi, Yokota, Toshifumi, Wood, Matthew J.A., Mouly, Vincent, Aoki, Yoshitsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2021
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997716/ https://www.ncbi.nlm.nih.gov/pubmed/33567244 http://dx.doi.org/10.1089/nat.2020.0907

Ejemplares similares

Scavenger Receptor Class A1 Mediates Uptake of Morpholino Antisense Oligonucleotide into Dystrophic Skeletal Muscle
por: Miyatake, Shouta, et al.
Publicado: (2019)

Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment
por: Gait, Michael J., et al.
Publicado: (2019)

Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics
por: McClorey, Graham, et al.
Publicado: (2018)

Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides
por: Järver, Peter, et al.
Publicado: (2015)

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2017)

Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy
por: Shabanpoor, Fazel, et al.
Publicado: (2015)

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2018)

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2018)

A functional human motor unit platform engineered from human embryonic stem cells and immortalized skeletal myoblasts
por: Abd Al Samid, Marwah, et al.
Publicado: (2018)

Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders
por: Mamchaoui, Kamel, et al.
Publicado: (2011)

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice
por: Betts, Corinne A., et al.
Publicado: (2015)

Dysferlin-deficient immortalized human myoblasts and myotubes as a useful tool to study dysferlinopathy
por: Philippi, Susanne, et al.
Publicado: (2012)

Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy
por: Betts, Corinne A., et al.
Publicado: (2015)

Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides
por: Turner, John J., et al.
Publicado: (2005)

Synthesis and Splice-Redirecting Activity of Branched, Arginine-Rich Peptide Dendrimer Conjugates of Peptide Nucleic Acid Oligonucleotides
por: Saleh, Amer F., et al.
Publicado: (2010)

Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
por: Aoki, Yoshitsugu, et al.
Publicado: (2013)

Fine Tuning of Phosphorothioate Inclusion in 2′-O-Methyl Oligonucleotides Contributes to Specific Cell Targeting for Splice-Switching Modulation
por: Aoki, Yoshitsugu, et al.
Publicado: (2021)

In Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy
por: Echigoya, Yusuke, et al.
Publicado: (2015)

Cell penetrating peptide conjugates of steric block oligonucleotides()
por: Lebleu, Bernard, et al.
Publicado: (2008)

Cellular and Genomic Features of Muscle Differentiation from Isogenic Fibroblasts and Myoblasts
por: Benarroch, Louise, et al.
Publicado: (2023)

Antisense PMO Found in Dystrophic Dog Model Was Effective in Cells from Exon 7-Deleted DMD Patient
por: Saito, Takashi, et al.
Publicado: (2010)

Covalently attached intercalators restore duplex stability and splice-switching activity to triazole-modified oligonucleotides
por: Dysko, Anna, et al.
Publicado: (2022)

Mutation Types and Aging Differently Affect Revertant Fiber Expansion in Dystrophic Mdx and Mdx52 Mice
por: Echigoya, Yusuke, et al.
Publicado: (2013)

Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System
por: Lattanzi, Annalisa, et al.
Publicado: (2017)

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment
por: Betts, Corinne, et al.
Publicado: (2012)

Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy
por: Malerba, Alberto, et al.
Publicado: (2012)

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology
por: van Westering, Tirsa L.E., et al.
Publicado: (2019)

Modulating the Expression of Disease Genes with RNA-Based Therapy
por: Wood, Matthew, et al.
Publicado: (2007)

Hematopoietic Cell Transplantation Provides an Immune-tolerant Platform for Myoblast Transplantation in Dystrophic Dogs
por: Parker, Maura H, et al.
Publicado: (2008)

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
por: Veltrop, Marcel, et al.
Publicado: (2018)

Ensemble-Learning and Feature Selection Techniques for Enhanced Antisense Oligonucleotide Efficacy Prediction in Exon Skipping
por: Zhu, Alex, et al.
Publicado: (2023)

Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy
por: Nguyen, Quynh, et al.
Publicado: (2017)

Pharmacological activation of SERCA ameliorates dystrophic phenotypes in dystrophin-deficient mdx mice
por: Nogami, Ken'ichiro, et al.
Publicado: (2021)

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
por: Miskew Nichols, Bailey, et al.
Publicado: (2016)

Elastase levels and activity are increased in dystrophic muscle and impair myoblast cell survival, proliferation and differentiation
por: Arecco, N., et al.
Publicado: (2016)

LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts
por: Touznik, Aleksander, et al.
Publicado: (2017)

Simplified in vitro engineering of neuromuscular junctions between rat embryonic motoneurons and immortalized human skeletal muscle cells
por: Saini, Jasdeep, et al.
Publicado: (2019)

Evaluation of Amphiphilic Peptide Modified Antisense Morpholino Oligonucleotides In Vitro and in Dystrophic mdx Mice
por: Wang, Mingxing, et al.
Publicado: (2017)

Splice-Switching Therapy for Spinal Muscular Atrophy
por: Meijboom, Katharina E., et al.
Publicado: (2017)

Tetraploidization of Immortalized Myoblasts Induced by Cell Fusion Drives Myogenic Sarcoma Development with DMD Deletion
por: Merle, Candice, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_omlb012ro54s2t57s7us2427t2